1. What percentage of HIV-infected patients are coinfected with HCV infection?
A. 1%
B. 5%
C. 25%
D. 50%
2. Which of the following represents the most likely route of transmission for new HIV infections in men within the U.S.?
A. Injection drug use
B. Male-to-male sexual contact
C. Heterosexual contact
D. Blood transfusion
3. The most common HCV genotype in the U.S. is which of the following:
A. Genotype 1
B. Genotype 2
C. Genotype 4
D. Genotype 6
4. According to the most recent CDC guidance, which of the following patients should be screened for HIV infection at least annually?
A. 22-year-old single female who had a negative HIV screening test 6 months ago and has no risk factors for HIV during the past year
B. 43-year-old male patient who is an injection drug user
C. 68-year-old married female patient in a monogamous relationship with her husband of 40 years
D. 38-year-old single male who has sex with men, had a negative HIV screening test 1 year ago, and has not been sexually active during the past year
5. Which of the following is a goal of antiretroviral therapy in HIV-infected patients?
A. Prevent HIV transmission.
B. Restore and preserve immunologic function.
C. Maximally and durably suppress plasma HIV viral load.
D. All of the above
6. A sustained virologic response in a patient treated for HCV is defined as:
A. The continued absence of detectable HCV RNA at least 4 weeks following completion of HCV therapy
B. The continued absence of detectable HCV RNA at least 8 weeks following completion of HCV therapy
C. The continued absence of detectable HCV RNA at least 12 weeks following completion of HCV therapy
D. None of the above
7. Which of the following antiretroviral therapy choices is a recommended regimen for an antiretroviral-naive HIV-infected patient?
A. Dolutegravir + tenofovir disoproxil fumarate/emtricitabine
B. Efavirenz/tenofovir/emtricitabine
C. Abacavir/lamivudine/zidovudine
D. Tipranavir + lamivudine/zidovudine
8. Which of the following HCV choices represents a recommended regimen for a treatment-naive HCV-infected patient with genotype 1a?
A. Daily simeprevir (150 mg) plus sofosbuvir (400 mg) x 12 weeks for patients without cirrhosis
B. Daily fixed-dose combination of elbasvir (50 mg)/grazoprevir (100 mg) x 12 weeks for patients with or without cirrhosis
C. Daily fixed-dose combination of ledipasvir (90 mg)/sofosbuvir (400 mg) x 12 weeks for patients with or without cirrhosis
D. All of the above
9. Which of the following is the most appropriate dose of daclatasvir in a patient who is concomitantly being placed on an efavirenz-containing HIV regimen?
A. Daclatasvir 60 mg daily
B. Daclatasvir 90 mg daily
C. Daclatasvir 30 mg daily
D. Daclatasvir 10 mg daily
10. With which of the following antiretrovirals should ribavirin not be combined because of concern for an increased risk for worsening anemia?
A. Lamivudine
B. Emtricitabine
C. Dolutegravir
D. Zidovudine
Evaluation Questions
11. To what extent did the program meet objective #1?
A. Excellent
B. Very Good
C. Good
D. Fair
E. Poor
12. To what extent did the program meet objective #2?
A. Excellent
B. Very Good
C. Good
D. Fair
E. Poor
13. To what extent did the program meet objective #3?
A. Excellent
B. Very Good
C. Good
D. Fair
E. Poor
14. To what extent did the program meet objective #4?
A. Excellent
B. Very Good
C. Good
D. Fair
E. Poor
15. To what extent did the program meet objective #5?
A. Excellent
B. Very Good
C. Good
D. Fair
E. Poor
16. Rate the effectiveness of how well the program related to your educational needs:
A. Excellent
B. Very Good
C. Good
D. Fair
E. Poor
17. Rate how well the active learning strategies (questions, cases, discussions) were appropriate and effective learning tools:
A. Excellent
B. Very Good
C. Good
D. Fair
E. Poor
18. Rate the quality of the faculty:
A. Excellent
B. Very Good
C. Good
D. Fair
E. Poor
19. Rate the effectiveness and the overall usefulness of the material presented:
A. Excellent
B. Very Good
C. Good
D. Fair
E. Poor
20. Rate the appropriateness of the examination for this activity:
A. Excellent
B. Very Good
C. Good
D. Fair
E. Poor
21. Rate the effectiveness of how well the activity related to your practice needs:
A. Excellent
B. Very Good
C. Good
D. Fair
E. Poor
22. Rate the effectiveness of how well the activity will help you improve patient care:
A. Excellent
B. Very Good
C. Good
D. Fair
E. Poor
23. Will the information presented cause you to change your practice?
A. Yes
B. No
24. Are you committed to making these changes?
A. Yes
B. No
25. As a result of this activity, did you learn something new?
A. Yes
B. No
26. What is your practice setting or area of practice?
A. Community Pharmacy/Independent
B. Community Pharmacy/Chain
C. Hospital/Health Systems
D. Administrative/Pharmacy Director
E. Critical Care Pharmacy
F. Long-term Care
G. Managed Care/PBM
H. Oncology
I. Specialty Pharmacy
J. Industry/Manufacturing
27. How many years have you been in practice?
A. <5
B. 5 – 10
C. 11 – 20
D. >20
E. >20
